{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-006302","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.181285+00:00","generated_at":"2026-05-26T01:09:15.368963+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rocket Pharma FY2024 net loss $258.7M ($2.73/sh); cash $372.3M; RP-A501 Phase 2 ongoing","bullets":["Net loss $258.7M ($2.73/sh) for FY2024 vs $245.6M ($2.92/sh) in FY2023.","Cash, equivalents and investments $372.3M at Dec 31, 2024; runway into Q3 2026.","Raised $182.5M net via Dec 2024 offering of 15.2M shares at $12.50/sh.","RP-A501 Phase 2 pivotal dosing ongoing; NEJM publication shows efficacy up to 5 years.","RP-A601 low dose cohort fully enrolled; initial data expected H1 2025. BAG3-DCM IND on track H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-006302","json":"https://secwatch.observer/filing/0001140361-25-006302.json","markdown":"https://secwatch.observer/filing/0001140361-25-006302.md","text":"https://secwatch.observer/filing/0001140361-25-006302.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125006302/0001140361-25-006302-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125006302/ef20044486_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T01:09:15.368963+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}